Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)
Status:
Completed
Trial end date:
2018-04-26
Target enrollment:
Participant gender:
Summary
This clinical study is in subjects who are 18 years old or older with locally advanced
pancreatic cancer who have not received prior treatment for their pancreatic cancer. The
study treats all subjects with nab-Paclitaxel plus gemcitabine for approximately 6 months of
treatment. Subjects who complete the treatment will choose, with their treating physicians,
what additional treatment should be given: more nab-Paclitaxel plus gemcitabine,
Chemoradiation therapy, or surgery to treat the locally advanced pancreatic cancer.